欧盟批准Dupixent用于慢性疹的幼儿. EU approves Dupixent for young children with chronic urticaria.

赛诺菲和雷杰伦宣布,欧盟委员会批准了杜普森特 (Dupixent),这是首个针对性药物,已获批用于治疗慢性自发疹的幼儿. Sanofi and Regeneron announced that the European Commission has approved Dupixent, the first targeted medicine approved to treat young children with chronic spontaneous urticaria. 这一批准标志着受该病影响的家庭的一个重要里程碑. This approval marks a significant milestone for families affected by the condition.